BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Autor: David M. Ross, Jodi Braley, Timothy P. Hughes, Phuong Dang, Ilaria S. Pagani, Ivar O. Kommers, Verity A Saunders, Deborah L. White, Jarrad M. Goyne, Susan Branford, Mario Nicola, David T Yeung

Publikováno v: Haematologica, 103(12), 2026-2032. Ferrata Storti Foundation
Pagani, I S, Dang, P, Kommers, I O, Goyne, J M, Nicola, M, Saunders, V A, Braley, J, White, D L, Yeung, D T, Branford, S, Hughes, T P & Ross, D M 2018, ' BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia ', Haematologica, vol. 103, no. 12, pp. 2026-2032 . https://doi.org/10.3324/haematol.2018.189787

Accurate quantification of minimal residual disease during treatment of chronic myeloid leukaemia guides clinical decisions. The conventional minimal residual disease method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f192487b3ee12867ce52e75cdfe094
https://doi.org/10.3324/haematol.2018.189787

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

Autor: Silvia Mori, Bruno Martino, Sarit Assouline, Micaela Bergamaschi, Eros Di Bona, Marcio Andrade-Campos, Chiara Elena, Patrizia Crivori, Ester Pungolino, Alessandra Iurlo, Antonella Gozzini, Philipp le Coutre, Elisa Diral, Elisabetta Abruzzese, Laura Antolini, Alessandra Pirola, Diletta Fontana, Fabio Stagno, Maria Luisa Bonanomi, Rocco Piazza, Carmen Fava, Carlo Gambacorti-Passerini, Jessica Petiti

TO THE EDITOR: The Imatinib Suspension and Validation (ISAV) study1 is a multicenter trial of imatinib discontinuation (ID) among patients with chronic myeloid leukemia (CML) in undetectable deep molecular remission (U-DMR). After 12 months of follow

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373ab22048a187785430319d1067b850
http://hdl.handle.net/10281/315442

Nilotinib significantly induces apoptosis in imatinib resistant K562 cells with wild-type BCR–ABL, as effectively as in parental sensitive counterparts

Autor: Geylani Can, Ufuk Gündüz, Yusuf Baran, Huseyin Atakan Ekiz

Publikováno v: Hematology. 15:33-38

Chronic myeloid leukemia (CML) is a hematological malignancy characterized by high levels of immature white blood cells. CML is caused by the translocation between chromosomes 9 and 22 (which results in the formation of the Philadelphia chromosome) c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba6a3bcd76ac7e8efec80fc74d3ca71
https://doi.org/10.1179/102453310x12583347009775

Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

Autor: Osman Ilhan, Rıdvan Ali, Zafer Baslar, Ibrahim C. Haznedaroglu, Orhan Ayyildiz, Diyar Z. Akkaynak, Ugur Ozbek, Leylagül Kaynar, Mehmet Sönmez, Demet Aydin, Akif Selim Yavuz, Bülent Ündar, Ilkiz M. Dag, Mustafa Pehlivan, Güray Saydam, Birol Guvenc, Olga Meltem Akay, Simten Dagdas

PubMed ID: 27501474
Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7978eceb03118408c2e8f7f3666597
https://hdl.handle.net/20.500.12605/18279

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.